CLEVELAND, Ohio, Aug. 30 [Category: BizHospital] -- The Cleveland Clinic posted the following news release: * * * Cleveland Clinic-Led Trials Shows Drug Doesn't Significantly Improve Outcomes in Patients with Non-Obstructive Hypertrophic Cardiomyopathy * Findings from a Cleveland Clinic -led clinical trial showed that the use of the drug, mavacamten in symptomatic, non-obstructive hypertrophic cardiomyopathy patients did not significantly reduce symptoms compared to placebo. Results from t  more

SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release: * * * Aficamten is superior to metoprolol for symptomatic obstructive hypertrophic cardiomyopathy * Beta-blockers are commonly used in the initial treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM), despite limited evidence of their efficacy. * The MAPLE-HCM trial compared the cardiac myosin inhibitor, aficamten, with the beta-blocker, metoprolol, as monotherapy, in  more

SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release: * * * Beta-blockers did not reduce cardiovascular events in selected heart attack patients in the REBOOT trial * While beta-blockers are a foundational treatment after acute myocardial infarction (MI) in patients with reduced left ventricular ejection fraction (LVEF), their role in patients with mildly reduced or preserved LVEF (>40%) is less certain. * The REBOOT trial demonstrated a   more

SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release: * * * Beta-blockers reduced cardiovascular events in selected heart attack patients without heart failure in the BETAMI-DANBLOCK trials * While beta-blockers are strongly recommended for patients with myocardial infarction (MI) and reduced left ventricular ejection fraction (LVEF), their role in patients with preserved or mildly reduced LVEF (40%) is less certain. * The BETAMI-DANBLOCK  more

SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release: * * * No improvements with mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy * There are currently no approved therapies for nonobstructive hypertrophic cardiomyopathy (HCM). * The ODYSSEY-HCM trial compared the cardiac myosin inhibitor, mavacamten, with placebo in patients with symptomatic nonobstructive HCM. * Mavacamten was not associated with significant improv  more

SOPHIA ANTIPOLIS, France, Aug. 30 -- The European Society of Cardiology issued the following news release: * * * Olezarsen reduces levels of the blood fat, triglycerides, in patients at high cardiovascular risk * An unmet need exists for effective therapies to lower triglyceride levels in patients with residual cardiovascular risk despite optimal lipid-lowering therapies. * The ESSENCE-TIMI 73b trial investigated the efficacy and safety of the apolipoprotein C-III RNA-targeting medicine, ol  more

LONDON, England, Aug. 30 (TNSjou) -- The University College London issued the following news: * * * Promising new drug for people with stubborn high blood pressure A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor. * Globally around 1.3 billion people have high blood pressure (hypertension), and in around ha  more